Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-008 in Advanced Solid Tumors
NCT06027346Phase 1Recruiting
- Sponsor
- Yiling Pharmaceutical
- Start
- Jul 2023
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of BIO-008 in solid tumor (advanced stage), gastric cancer (GC), gastroesophageal junction cancer and 1 more (7 arms), sponsored by Yiling Pharmaceutical. Primary endpoints: Adverse events (AE)/severe adverse events (SAE), Incidence of dose limiting toxicity (DLT) and 3 more. Started Jul 2023; status: recruiting.
02
Drugs
BIO-008
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)gastroesophageal junction cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06027346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027346.